Lumida
/LNSR
⌘K
LENSAR Inc

LENSAR Inc

LNSR
$5.80USD↑+2.29%+0.13 today

MARKET CAP

70.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $6

52W RANGE

$5
$13

AI Summary

Stalk
Sell NowMedium

LNSR remains in a Stage 4 decline with lower highs and lower lows driving a medium-term bearish bias. Short-term conditions are favorable for selling as price tightly tracks below declining EMAs near resistance. Long-term trend remains structurally bullish per upstream analysis but is overshadowed by current selling pressure. With no mean reversion permission and absent exhaustion signals, executing a sell now is recommended.

  • ↑Q1 recurring revenue: $12.6M (+9% YoY), comprising 94% of total revenue.
  • ↑Ally installed base: 205 systems; U.S. market share climbed to 23.4%.
  • ↓Q1 total revenue of $13.4M down 5% YoY due to weak system placements.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Lensar, Inc. (NASDAQ: LNSR) is an innovative medical technology company focused on laser-assisted cataract surgery, with its flagship product, the Ally system. The company aims to strengthen its market position following a disrupted period due to an abandoned merger with Alcon. Lensar is focused on expanding its operations independently, emphasizing recurring revenue growth linked to its system installations. As a player in the ophthalmic sector, it is positioned amid rising demand for advanced surgical technologies and improved patient outcomes.

Bull says

  • ↑Q1 recurring revenue: $12.6M (+9% YoY), comprising 94% of total revenue.
  • ↑Ally installed base: 205 systems; U.S. market share climbed to 23.4%.
  • ↑Procedure volume rose to ~54k in Q1 versus 52k YoY, boosting recurring fees.
  • ↑Management expects steady rebuild and tech adoption to drive future growth.
  • ↑Proprietary laser technology positions Lensar to replace obsolete cataract systems.
  • ↑Strong qualitative growth factor and high QS score reinforce upside potential.

Bear says

  • ↓Q1 total revenue of $13.4M down 5% YoY due to weak system placements.
  • ↓Operating loss widened to $2.2M as production and operating expenses climbed.
  • ↓Cash $13.5M may prove insufficient against mounting debt and cash burn.
  • ↓Elevated leverage risk and negative earnings yield raise financial sustainability concerns.
  • ↓Competition from Alcon, J&J, and Bausch + Lomb continues to pressure adoption.
  • ↓Negative momentum and profitability factors hint at potential stock volatility.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-13-2026neutral

Transcript signals

Bull points

  • Recurring revenue continued to be the bright spot in our performance, with total recurring revenue of $12.6 million, up 9% from the $11.5 million in the prior year quarter.
  • We expect upon achieving a rebound of our quarterly placements to see our adjusted EBITDA will return to positive territory and thereby again generate cash from operations.
  • With the termination of the merger not happening mid-March, we spent most of quarter one in this state of limbo, and that state of being was reflected in our results for the quarter. However, in a positive light, the FTC position and deal termination validated we have the best technology in the market.

Bear points

  • Our total revenue for the first quarter of 2026 was $13.4 million, compared with $14.2 million in the first quarter of 2025. The year-over-year decline was primarily due to lower system revenue, which was partially offset by continued growth in recurring revenue.
  • System revenue was approximately $800,000 this quarter, compared with $2.6 million in the prior year quarter, reflecting lower placement activity from our acquisition malaise Nick discussed earlier.
  • Moving on to adjusted EBITDA, which was negative $311,000 versus a positive $165,000 in the prior year quarter.
Read full transcript analysis ›